Advancing Maternal Health Screening in LMICs with AI-Powered Retinal Imaging by Remidio

Maternal health remains one of the most critical public health challenges worldwide, especially in low- and middle-income countries (LMICs) where the burden of pregnancy complications and maternal mortality is disproportionately high. Addressing this pressing issue, Remidio Innovative Solutions has been awarded a pivotal grant by the Gates Foundation to enhance its cutting-edge AI-powered retinal imaging platform — Oculomics — to improve screening and early risk assessment for major pregnancy complications such as pre-eclampsia, anemia, and gestational diabetes mellitus.

The Maternal Health Crisis in LMICs

The scale of maternal health challenges in LMICs is staggering. Globally, approximately 2 million stillbirths occur each year — equivalent to one every 16 seconds — with 84% of these deaths concentrated in these countries. Among the leading causes are hypertensive disorders of pregnancy, notably pre-eclampsia, which significantly contribute to stillbirths and maternal mortality. An estimated 42,000 maternal deaths annually are attributed to these conditions.

Gestational diabetes mellitus (GDM) also poses a significant risk, affecting roughly one in six pregnancies worldwide. Women in LMICs bear an especially high burden of GDM, which is associated with adverse outcomes including preterm births and long-term health complications affecting both mother and child.

Challenges in Maternal Health Screening

Early detection of pregnancy complications is critical but remains challenging due to the limited availability of diagnostic resources in primary and community healthcare settings within LMICs. Conventional screening methods for risk stratification—such as complex laboratory assays, biochemical biomarkers, and Doppler ultrasound assessments—require sophisticated infrastructure and trained personnel, which are often scarce or inaccessible for most pregnant women in these regions.

Consequently, many at-risk pregnancies go undetected until complications arise, reducing the effectiveness of interventions that could prevent adverse outcomes.

Innovative Solution: Retinal Imaging and AI Integration

Remidio’s Oculomics platform leverages smartphone-based portable retinal imaging combined with advanced artificial intelligence to provide a rapid, non-invasive method for detecting vascular and metabolic changes associated with pregnancy complications.

The retina offers a unique window into the body’s microvascular system, and changes in retinal blood vessels can indicate systemic diseases such as pre-eclampsia and gestational diabetes. Retinal imaging is quick, requires minimal training for frontline health workers, and can be scaled effectively within community healthcare settings.

Dr. Anand Sivaraman, CEO and Founding Director of Remidio, highlights, “A retinal image takes only seconds to capture and can be performed by frontline workers even in remote areas with limited medical infrastructure. This project aims to rigorously evaluate if our platform, already successful in diabetic retinopathy screening, can be similarly vital for early pregnancy risk detection where it is needed the most.”

Benefits of Retinal Imaging in Antenatal Care

• Non-invasive and quick: Enables efficient screening without discomfort or risk to the mother.
• Low resource requirement: Does not demand complex laboratory setups or highly specialized personnel.
• Scalable and accessible: Portable technology facilitates widespread use in community-level healthcare.
• Early risk assessment: Detects markers that predict complications, allowing timely interventions.

Implementation Across Africa and India

The initiative targets areas in Africa and India, regions that bear the largest share of the global maternal and perinatal disease burden. By deploying this technology in partnership with local healthcare programs, Remidio aims to improve prenatal screening and ultimately reduce maternal and neonatal mortality rates.

Dr. Divya Rao, Chief Medical Officer and Head of AI at Remidio, emphasizes the importance of evidence-based validation: “While the biological link between retinal microvascular changes and systemic disease is established, our goal is to demonstrate effectiveness in real-world community antenatal care settings across diverse populations, empowering frontline workers to deliver better care.”

Looking Ahead: Transforming Maternal Healthcare

Remidio’s retinal imaging platform, successful in screening diabetic retinopathy, glaucoma, and age-related macular degeneration, is poised to revolutionize how maternal health is monitored in resource-limited environments. This grant not only expands the platform’s capabilities but also marks a critical step toward scalable, accessible, and effective maternal screening solutions.

By integrating innovative technology and AI with community healthcare, this project represents a promising advancement to tackle pregnancy complications head-on and improve outcomes for millions of women and newborns globally.

For more information about Remidio’s work and developments in maternal health technology, stay connected to trusted healthcare news and updates.